A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced non-small cell lung cancer (NSCLC).
文献类型：期刊论文
| 作者 | Zhou, Caicun; Ren, Shengxiang; Luo, Yongzhong; Wang, Lei; Xiong, Anwen; Su, Chunxia; Zhang, Zhihong; Li, Wei; Zhou, Jin; Yu, Xinmin |
| 刊名 | JOURNAL OF CLINICAL ONCOLOGY
 |
| 出版日期 | 2022-06-01 |
| 卷号 | 40 |
| ISSN号 | 0732-183X |
| 资助项目 | Akeso Biopharma, Inc. |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000863680302227 |
| 出版者 | LIPPINCOTT WILLIAMS & WILKINS |
| 资助机构 | Akeso Biopharma, Inc. |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/129835]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 作者单位 | 1.WMU, Yuying Childrens Hosp, Wenzhou, Peoples R China 2.Shanghai Pulm Hosp, Oncol Dept, Shanghai, Peoples R China 3.Shanghai Pulm Hosp, Shanghai, Peoples R China 4.Hunan Canc Hosp, Thorac Dept, Changsha, Peoples R China 5.Anhui Prov Canc Hosp, Dept Resp Oncol, Hefei, Peoples R China 6.Canc Hosp Sichuan Prov, Dept Med Oncol, Chengdu, Peoples R China 7.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Thorac Oncol, Hangzhou, Peoples R China 8.Hubei Canc Hosp, Dept Thorac Oncol, Wuhan, Peoples R China 9.Canc Hosp Nantong, Dept Med Oncol, Nantong, Peoples R China 10.Huazhong Univ Sci & Technol, Union Hosp, Tongi Med Coll, Wuhan, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhou, Caicun,Ren, Shengxiang,Luo, Yongzhong,et al. A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced non-small cell lung cancer (NSCLC).[J]. JOURNAL OF CLINICAL ONCOLOGY,2022,40. |
| APA | Zhou, Caicun.,Ren, Shengxiang.,Luo, Yongzhong.,Wang, Lei.,Xiong, Anwen.,...&Xia, Yu.(2022).A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced non-small cell lung cancer (NSCLC)..JOURNAL OF CLINICAL ONCOLOGY,40. |
| MLA | Zhou, Caicun,et al."A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced non-small cell lung cancer (NSCLC).".JOURNAL OF CLINICAL ONCOLOGY 40(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。